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Glycosylation is an essential post-translational modi-
fication that underliesmany biological processes and
diseases. a-dystroglycan (a-DG) is a receptor forma-
trix and synaptic proteins that causes muscular dys-
trophy and lissencephaly upon its abnormal glycosyl-
ation (a-dystroglycanopathies). Here we identify the
glycan unit ribitol 5-phosphate (Rbo5P), aphosphoric
ester of pentose alcohol, in a-DG. Rbo5P forms a tan-
dem repeat and functions as a scaffold for the forma-
tion of the ligand-binding moiety. We show that
enzyme activities of three major a-dystroglycanop-
athy-causing proteins are involved in the synthesis
of tandem Rbo5P. Isoprenoid synthase domain-con-
taining (ISPD) is cytidine diphosphate ribitol (CDP-
Rbo) synthase. Fukutin and fukutin-related protein
are sequentially acting Rbo5P transferases that
use CDP-Rbo. Consequently, Rbo5P glycosylation
is defective in a-dystroglycanopathy models. Sup-
plementation of CDP-Rbo to ISPD-deficient cells
restored a-DG glycosylation. These findings estab-
lish the molecular basis of mammalian Rbo5P glyco-
sylation and provide insight into pathogenesis and
therapeutic strategies in a-DG-associated diseases.
INTRODUCTION
a-dystroglycan (a-DG) was originally identified as a laminin re-
ceptor in the dystrophin-glycoprotein complex that is defectiveCein Duchenne muscular dystrophy (Ibraghimov-Beskrovnaya
et al., 1992). Subsequently, several matrix and synaptic proteins
such as agrin, perlecan, and neurexin were identified as a-DG
ligands (Yoshida-Moriguchi and Campbell, 2015). a-DG also
functions as a receptor for Lassa virus (Cao et al., 1998).
O-mannose (Man)-type glycosylation of a-DG is required for its
ligand-binding activities, and abnormal glycosylation is associ-
ated with muscular dystrophy, lissencephaly, and cancer metas-
tasis (Michele et al., 2002; Bao et al., 2009). Several genes have
been identified to be responsible for a-dystroglycanopathy, a
group of muscular dystrophies caused by aberrant a-DG glyco-
sylation (Yoshida-Moriguchi and Campbell, 2015). a-dystrogly-
canopathy includes Fukuyama congenital muscular dystrophy
(FCMD), muscle-eye-brain disease, Walker-Warburg syndrome,
congenital muscular dystrophy (MDC) 1C/1D, and limb-girdle
muscular dystrophy (LGMD) 2I. Fukutin is the causative gene
for FCMD, and we have demonstrated that splicing-modulation
therapy by antisense oligonucleotides is a promising clinical
treatment for FCMD (Kobayashi et al., 1998; Taniguchi-Ikeda
et al., 2011).
Some a-dystroglycanopathy gene products (POMGnT1,
POMT1, and POMT2) are glycosyltransferases that synthe-
size the initially identified O-Man-type CoreM1 glycan
[Galb1,4GlcNAcb1,2Man-] (Yoshida et al., 2001; Manya et al.,
2004; Chiba et al., 1997). Recently, another O-Man glycan
[GalNAcb1,3GlcNAcb1,4Man-], CoreM3, was identified in re-
combinant a-DG (Yoshida-Moriguchi et al., 2010), and several
other a-dystroglycanopathy genes were also subsequently iden-
tified (Jae et al., 2013; Willer et al., 2012; Roscioli et al., 2012).
The recently identified a-dystroglycanopathy genes GTDC2
(POMGNT2) and B3GALNT2 encode glycosyltransferases that
synthesize the CoreM3 glycan (Yoshida-Moriguchi et al., 2013).ll Reports 14, 2209–2223, March 8, 2016 ª2016 The Authors 2209
SGK196 (POMK) encodes a kinase that phosphorylates the
C6 position of O-Man in CoreM3 (Yoshida-Moriguchi et al.,
2013). The glycan structure directly involved in ligand binding
is [-3Xyla1,3GlcAb1-]n (hereafter referred to as the Xyl/GlcA
repeat), which is synthesized by the glycosyltransferase LARGE
(Inamori et al., 2012). It has been hypothesized that the Xyl/GlcA
repeat branches from the phosphorylated O-Man in CoreM3 via
a putative phosphodiester-linked moiety (Yoshida-Moriguchi
et al., 2010). This is called a ‘‘post-phosphoryl moiety’’; however,
its structure is still unknown. In addition, the presence of a-dys-
troglycanopathy genes with unknown functions (fukutin, FKRP,
ISPD, and TMEM5) suggests that an additional moiety and a syn-
thetic pathway for a-DG maturation likely exist. To answer these
questions and to better understand the pathogenesis of the
a-dystroglycanopathies, we attempted to delineate the full func-
tional glycan structure of a-DG.
RESULTS
Identification of Ribitol 5-Phosphate in the Sugar Chain
of a-DG
For mass spectrometry (MS)-based structural analysis, we de-
signed a small recombinant a-DG/Fc fusion protein, DGFcWT,
which contains the wild-type (WT) N-terminal domain and the
first 20 amino acids of the mucin-like domain (from Ala314 to
Pro333) (Figure 1A). Mature a-DG-Fc peptides begin with
Gln311 because the N-terminal domain is processed during
maturation (Kanagawa et al., 2004) and LARGE-dependent
glycosylation takes place on the first two Thr residues in the
mucin-like domain (Thr315 and Thr317) (Hara et al., 2011b).
The results of western blotting using the IIH6 antibody, which
recognizes the Xyl/GlcA repeat, and a laminin overlay assay sug-
gested that DGFcWT is modified with the Xyl/GlcA repeat and
possesses laminin-binding activity in NIH 3T3 cells without
LARGE overexpression (Figure 1B). To obtain glycopeptides
that contain a functional moiety, we subjected the samples to
an anion exchange column after removing the Fc tag, terminal
sialic acids, and O-GalNAc-type glycans (Figure 1A). A step-
wise elution with ammonium acetate (NH4Ac) enabled us to frac-
tionate the DGFcWT-derived glycopeptides (DGWT-GPs) accord-
ing to the length of the negatively charged Xyl/GlcA repeat. MS of
the fractions eluted with 0.5M and 0.75MNH4Ac showed ladder
peaks that differed from each other by 308.2 Da, which corre-
sponded to the mass of a Xyl/GlcA unit (132.1 Da for Xyl and
176.1 Da for GlcA) (Figures 1C and 1D). The mass spectrum sug-
gested the presence of at least 13 Xyl/GlcA repeats, which were
sufficient for a-DG to bind laminin (Goddeeris et al., 2013). To
expose the structure connecting the Xyl/GlcA repeat to O-Man
glycan, we removed the Xyl/GlcA repeats by introducing a
T190M missense mutation in the N-terminal domain; this muta-
tion, identified in a patient with a-dystroglycanopathy, prevents
LARGE-dependent glycosylation (Hara et al., 2011a) (Figure 1A).
DGFcT190M did not react with laminin or the IIH6 antibody (Fig-
ure 1B). In contrast to DGWT-GPs, DGT190M-GPs from the
0.5 M NH4Ac eluate did not have the 308 Da repeats and instead
contained a GP of 6,138 Da (m/z 6,139.1; GP6138) and an ungly-
cosylated peptide (3,536 Da; m/z 3,537.1) (Figure 1E). Further-
more, the mass spectrum of DGWT-GPs from the 0.5 M NH4Ac2210 Cell Reports 14, 2209–2223, March 8, 2016 ª2016 The Authorseluate suggested that the Xyl/GlcA repeat stemmed from
GP6138 (6,139.1 plus a Xyl/GlcA unit corresponded to the first
ladder signal at 6,447.4) (Figures 1C and 1E). Indeed, LARGE
added the Xyl/GlcA repeat to GP6138 from DGT190M-GPs
in vitro (Figure S1), indicating that GP6138 contains the core
acceptor structure for LARGE-dependent modifications.
It has been conceived that the Xyl/GlcA modification requires
a phosphodiester-linked structure (Yoshida-Moriguchi et al.,
2013). To identify the phosphodiester-linked structure, DGWT-
GPs from the 0.75MNH4Ac eluate were treatedwith hydrofluoric
acid (HF), which cleaves the phosphodiester linkage of a-DG
(Yoshida-Moriguchi et al., 2010) and DGFc proteins, resulting
in a loss of IIH6 reactivity (Figure 1F). After treatment, the
peaks in the high mass region converged into two major ions
at m/z 5,402.7 and m/z 5,322.7 (Figure 1G), of which the mass
of the former ion corresponded well to the GP containing one
phosphorylated CoreM3 glycan (Yoshida-Moriguchi et al.,
2010), two CoreM1 glycans (Chiba et al., 1997), and one hexose
moiety (Figure 2A, green background). The ion at m/z 5,322.7
corresponds to the same GP that lacks a phosphate. These re-
sults suggest that GP6138 contains a phosphodiester-linked
structure of 736.5 Da (6,139.1 minus 5,402.7; hereafter, we
describe this moiety as ‘‘Structure736’’) (Figure 2A, blue back-
ground). To identify the components of Structure736, we treated
the GP6138-rich fractions from the DGT190M-GPs with HF and
then subjected the ions in the low mass region to MS/MS. The
MS/MS spectrum suggests that Structure736 contains a termi-
nal Xyl/GlcA unit and an alternating repeat of 80 Da and
134 Da (Figures S2A–S2D). The high resolving power MS eluci-
dated the precise mass of the 134 Da component to be
134.05787 or 134.05791, specifying the elemental composition
as C5H10O4 (134.05791 Da for theoretical mass) (Figure 2B).
Similarly, the 80 Da moiety was identified as PO3H (79.96633)
rather than SO3 (79.95682) (Figure 2B).
Tomore easily enable tandemMS for the GPs, we constructed
a mutant, DGFcT320K, which results in a small peptide following
lysylendopeptidase (LEP) digestion (Figure 1A). This DGFc
mutant was properly modified with the laminin-binding glycan
(Figure 1B). We prepared DGT320K-GP of 2,986 Da (GP2986),
which corresponds to a glycopeptide (QIHATPTPVK) with one
phosphorylated CoreM3, one CoreM1, and Structure736, and
then subjected it to MS/MS. The results confirmed that
GP2986 contains the 80 Da and 134 Da repeat, which is linked
to the terminal Xyl/GlcA unit and the core HexNAc-HexNAc at
each end (Figure S2E). More intriguingly, the presence of the
product ion at m/z 1,452.2 from the precursor indicates that
Structure736 is not attached to the phosphate of the innermost
O-Man residue.
There were three candidate residues with the chemical for-
mula C5H12O5 (hydrated C5H10O4): xylitol, D/L-arabitol, and ribi-
tol (Rbo). However, mammalian cells are not known to utilize
these compounds for post-translational modifications. Interest-
ingly, microorganisms, such as Gram-positive bacteria, use a
repeating unit of ribitol 5-phosphate (Rbo5P), which forms a
phosphodiester-linked polyol structure, teichoic acid, as a major
cell wall component (Brown et al., 2013). We hence performed
composition analysis of DGFcT190M using gas chromatography
(GC)-MS and detected three peaks (Gp1, Gp2, and Gp3) with
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Figure 1. Characterization of the DGFc Proteins
(A) Schematic representation of the a-DG constructs and their amino acid sequences. Mouse a-DG is composed of N-terminal, mucin-like, and C-terminal
domains. A protease cleavage site was inserted between the a-DG and Fc portions (brown). The asterisk indicates themissense T190Mmutation. (Right) Scheme
for purification of the glycopeptides.
(B) Western blot analysis and laminin overlay assay of the DGFc proteins. DGFc (full-length), DGFcWT, DGFcT190M, and DGFcT320K were subjected to western
blotting with a biotinylated anti-Fc antibody, IIH6 antibody, and to the laminin overlay assay.
(C–E) MALDI mass spectra of DGFc-derived glycopeptides. (C) DGWT-GP (0.5 M NH4Ac). (D) DG
WT-GP (0.75 M NH4Ac). (E) DG
T190M-GP (0.5 M NH4Ac).
(F) HF treatment of the DGFc proteins. DGFcWT, DGFcT190M, and DGFcT320K with (+) or without () HF treatment were analyzed by western blotting with IIH6 and
anti-Fc antibodies.
(G) MALDI mass spectra of HF-treated DGWT-GP (0.75 M NH4Ac).
See also Figure S1.similar retention times as the standard Rbo5P (Rp1, Rp2, and
Rp3) (Figure 3A). The mass spectra of these peaks are highly
matched to those of species with the structural formulas of anhy-Cedrous acetylated Rbo and acetylated Rbo (Figure 3B). We also
confirmed that this GC analysis is able to distinguish Rbo from
xylitol and arabitol (data not shown). These data indicate thatll Reports 14, 2209–2223, March 8, 2016 ª2016 The Authors 2211
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Figure 2. High-Resolution MS Analysis of a-DG
(A) Schematic representation of the sugar components of DG-GP; Structure736 (blue), the CoreM3 glycan (green), and the Xyl/GlcA repeat (orange).
(B) High-resolutionMS. The product ionmass spectrum from the precursors atm/z 367 for double charge orm/z 735 for single charge suggests that Structure736
contains a Xyl/GlcA unit (orange arrows) andmoieties consisting of 80 Da and 134 Da (blue arrows). The fragments of the 134 Da and 80 Damoieties (indicated by
a, b, and c) were cross-referenced to the exact mass database, and the results are shown in the table.
See also Figure S2.DGFcT190M contains Rbo residues and that themoiety consisting
of 80 Da and 134 Da structures is Rbo phosphate (RboP).
ISPD Is a CDP-Ribitol Synthase
In Gram-positive bacteria, the Rbo5P polymer is synthesized by
the TarK and TarL enzymes (Tar; Teichoic acid ribitol), which
use CDP-Rbo as a donor substrate, and CDP-Rbo is synthesized
by the TarI enzyme from cytidine triphosphate (CTP) and Rbo5P
(Brownet al., 2013).We found thatbacterial TarI sharedhomology
with mammal ISPD, which is one of the causative gene products
fora-dystroglycanopathy (Figure S3A) (Willer et al., 2012; Roscioli
et al., 2012). To determine whether ISPD possesses CDP-Rbo
synthase activity, we prepared His-tagged human ISPD, incu-
bated it with CTP and Rbo5P, and then analyzed the products
by high-performance liquid chromatography (HPLC). After the re-
action of ISPD with both Rbo5P and CTP, a novel peak was de-
tected (Figure 4A, indicated by ‘‘P’’), and the same peak was
observed in the TarI enzyme products (Figure S3B). MS results
of both products showed the same mass of 537 Da, which was
compatible with CDP-Rbo (Figures 4B and S3C). Thus, the enzy-
matic properties of human ISPDwere identical to those of bacte-
rial TarI. Pathogenic mutations of the ISPD gene impaired
CDP-Rbo synthesizing activity (Figures 4C and S3A). These
data indicate that ISPD is a mammalian CDP-Rbo synthase.
Fukutin and FKRPAre Ribitol 5-Phosphate Transferases
The fukutin family is predicted to encode a phosphoryl-ligand
transferase (Aravind and Koonin, 1999; Kuchta et al., 2009).2212 Cell Reports 14, 2209–2223, March 8, 2016 ª2016 The AuthorsFukutin-related protein (FKRP) was originally identified as a
causative gene for MDC1C/LGMD2I based on its sequence ho-
mology with fukutin (Brockington et al., 2001a). Both fukutin and
FKRP proteins contain the putative catalytic DXD motif, which is
a conservedmotif found in many families of glycosyltransferases
(Wiggins and Munro, 1998; Tachikawa et al., 2012; Esapa et al.,
2002). Therefore, we examined whether fukutin and FKRP are
involved in RboP modification. A synthetic peptide mimicking
mouse a-DG (ATPAPVAAIGPK) was enzymatically modified
with phosphorylated CoreM3 (phosphoCoreM3-peptide) (see
Supplemental Experimental Procedures) and then used as an
acceptor substrate. Fukutin and FKRP were prepared as
secreted proteins with a His/myc-tag at the N terminus (s-fukutin
and sFKRP, respectively). First, we incubated s-fukutin with
CDP-Rbo and phosphoCoreM3-peptide and then conducted
HPLC and MS analyses. A novel peak was detected in the pres-
ence of s-fukutin (Figure 5A, indicated as ‘‘P1’’), and this product
showed an increase in 214 Da (compatible with a RboP) from
phosphoCoreM3-peptide (1,997.0 minus 1,782.9; Figure 5B).
These data indicate that s-fukutin transfers Rbo5P from CDP-
Rbo to phosphoCoreM3-peptide. Missense mutations found in
FCMDpatients and in the putative catalytic sites reduced s-fuku-
tin enzyme activity (Figures 5C and S4A).
To examine whether FKRP also has Rbo5P transferase
activity, we incubated sFKRP with CDP-Rbo and either
phosphoCoreM3-peptide or Rbo5P-phosphoCoreM3-peptide.
Although sFKRP did not react with phosphoCoreM3-peptide,
its reaction with Rbo5P-phosphoCoreM3-peptide produced a
Figure 3. Identification of Ribitol-Phosphate in a-DG
(A) Gas chromatogram of the alditol acetate derivatives of Rbo5P (top) and DGFcT190M (bottom). The Rp1, Rp2, and Rp3 peaks correspond with those of Gp1,
Gp2, and Gp3, respectively.
(B) GC-MS of Rbo5P and DGFcT190M. The Rp1, Gp1, Rp3, and Gp3 peaks shown in (A) were analyzed by MS. The mass spectra of these peaks were cross-
referenced to the NIST database. The matched spectra with structural formulas are shown in the bottom panels.
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AC
B Figure 4. ISPD Is a CDP-Rbo Synthase
(A and B) Enzymatic activity of human ISPD. ISPD
enzyme reactions were performed with or without
Rbo5P, and the products were analyzed by HPLC.
S, unreacted acceptor substrate. P, enzyme prod-
uct. The fraction including the reaction products
(the peak designated asP inA) was analyzed byMS
in the negative ion mode (B).
(C) Enzyme activities of the ISPD mutants. Quan-
tities of the mutant proteins were confirmed to be
comparable by western blotting.
See also Figure S3.novel peak (Figure 5D, indicated as ‘‘P2’’) and the product
showed an increase in mass of 214 Da (2,211.1 minus 1,997.0;
Figures 5B and 5E). These data indicate that sFKRP transfers
the second Rbo5P to the s-fukutin products. Missense muta-
tions found in a-dystroglycanopathy patients and in the putative
catalytic sites reduced sFKRP enzyme activity (Figures 5F
and S4A). Finally, we fractionated mouse liver membrane
preparations and performed fukutin and FKRP enzyme assays
(Figure S4B). The distributions of both enzyme activities were
similar to the distribution of a Golgi marker protein, which sug-
gest that fukutin and FKRP activities reside in the Golgi
apparatus.
Determination of the Tandem Ribitol Structure
To determine the precise structure of the fukutin-dependent
moiety, we conducted large-scale preparation of s-fukutin prod-
ucts using the acceptor substrate GalNAcb1,3GlcNAcb-pNp
(pNp, p-nitrophenyl). We confirmed that s-fukutin can transfer
Rbo5P to GalNAcb1,3GlcNAcb-pNp (Figures S4C and S4D).
The original acceptor substrate (GalNAcb1,3GlcNAcb-pNp)
and the purified s-fukutin product were analyzed by a series of
NMR measurements, including 1H-13C heteronuclear single
quantum correlation (HSQC) and 2D 1H-31P heteronuclear
multiple-bond correlation (HMBC). In the 1H-13C HSQC spectra,
a 13C downfield shift (4 ppm) was observed at the GalNAc
C3 position after the s-fukutin reaction (Figures 6A and S5A).2214 Cell Reports 14, 2209–2223, March 8, 2016 ª2016 The AuthorsImportantly, a through-bond 1H-31P cor-
relation was observed in the s-fukutin
product between the phosphorus and
GalNAc H3 (Figure 6A). Thus, Rbo5P
is linked to the C3 position of GalNAc
via a phosphodiester linkage (Rbo5P-
3GalNAc). Therefore, fukutin is an enzyme
that transfers Rbo5P from CDP-Rbo to
the C3 position of GalNAc in the CoreM3
glycan (CDP-Rbo: GalNAc-3 Rbo5P
transferase).
Todetermine the precise structure of the
FKRP-dependent moiety, we performed
large-scalepreparationof sFKRPproducts
from Rbo5P-3GalNAcb1,3GlcNAcb-pNp
(Figures S4E and S4F), and analyzed
them by 1H-13C HSQC and 2D 1H-31P
HMBC experiments. In the 1H-13C HSQCspectra, significant chemical shift changes were observed for
the signals originating from the first Rbo5P residue (Rbo-C1 in
Glycan2 and Glycan3), and additional peaks were detected
from the second Rbo residue (Rbo’; Figures 6B and S5A). Fur-
thermore, a through-bond 1H-31P correlation was observed in
the sFKRP product between the phosphorus of the second
Rbo5P residue (Rbo’5P) and the H1 of the first Rbo5P residue
(Figure 6B). These NMR data revealed that the second Rbo
(Rbo’) is attached to the C1 position of the first Rbo residue via
a phosphodiester linkage (Figures 6B and S5A). Therefore,
FKRP is an enzyme that transfers the Rbo5P from CDP-Rbo to
the C1 position of the first Rbo5P (CDP-Rbo: Rbo5P-1 Rbo5P
transferase).
We further analyzed the Rbo5P-modified products that
were enzymatically synthesized, by 1D 31P NMR analysis (Fig-
ure 6C). PhosphoCoreM3-peptide showed a signal originating
from Man-6-phosphate (Man6P). A peak at 3 ppm was
observed in both Rbo5P-3GalNAcb1,3GlcNAcb-pNp and
Rbo5P-phosphoCoreM3-peptide, which was assigned to the
phosphorous of the first Rbo5P residue. The products of the
sFKRP reaction (Rbo’5P-1Rbo5P-3GalNAcb1,3GlcNAcb-pNp
and Rbo’5P-1Rbo5P-phosphoCoreM3-peptide) showed an
additional peak (2 ppm), which was assigned to the phos-
phorous from the second Rbo5P (Rbo’5P). The 1D 31P spec-
trum of purified DGT190M-GP6138 showed three signals, likely
originating from Man6P, the first Rbo5P, and the second
Rbo5P (Rbo’5P). Thus, the tandem Rbo5P moiety is present
in the a-DG protein expressed in mammalian cells. Finally,
to corroborate that the tandem Rbo5P is not modified on
the Man6P residue in the CoreM3 glycan, we analyzed the
s-fukutin and sFKRP products from phosphoCoreM3-peptide
by NMR (Figures S5B–S5D). The GalNAc-C3 and Rbo-C1
signals showed significant chemical shift changes after the
s-fukutin and sFKRP reactions, respectively; however, the
chemical shift of the Man-C6 signal did not change after
the reactions. These observations support that the tandem
Rbo5P moiety extends from the GalNAc residue, and not
from the Man residue, in the CoreM3 glycan (Figure 6D).
Defects of Ribitol 5-Phosphate Glycosylation in
a-Dystroglycanopathy Models and Potential
Therapeutic Strategies
To examine whether Rbo5P glycosylation is affected in a-dys-
troglycanopathy, we generated HAP1 cells with a disruption in
ISPD, fukutin, or FKRP genes as disease models, by CRISPR/
Cas9 gene editing (Figure S6). We confirmed the disruption
of functional a-DG glycosylation in these cells by western
blot analysis using the IIH6 antibody. Rescue experiments
confirmed that the abnormal glycosylation was caused by a
loss of the targeted genes. We first expressed DGFcWT in
normal HAP1 cells and analyzed DGWT-GPs from the 0.25 M
and 0.5 M NH4Ac eluates by MS (Figures 7A and 7B). The
data indicated the presence of ions containing Structure736
in the DGWT-GP preparations and that the Xyl/GlcA units
were modified on these GPs (Figure 7B). We then performed
MS analyses on DGWT-GPs prepared from the HAP1 cells
with each a-dystroglycanopathy gene defect. Although the
ions containing the phosphorylated CoreM3 glycan were de-
tected in the ISPD- or fukutin-disrupted cells, no signals were
assigned to GPs containing the Rbo5P moiety (Figures 7C
and 7D). These data indicate that DGWT-GPs prepared from
ISPD- or fukutin-disrupted HAP1 cells lacked Structure736
and also support the idea that fukutin acts as a priming enzyme
for Rbo5P modification. In the FKRP-disrupted cells, GPs
containing a portion of Strucuture736 (single Rbo5P, 214 Da)
were observed (Figure 7E), which supports the idea that
FKRP synthesizes the second Rbo5P in the tandem structure.
Taken together, these results confirmed that ISPD, fukutin,
and FKRP are required for the synthesis of the tandem
Rbo5P structure and indicate that Rbo5P glycosylation defects
cause the loss of functional glycosylation of a-DG, resulting in
a-dystroglycanopathy.
Our data also suggest that formation of the tandem Rbo5P
structure requires CDP-Rbo and that ISPD-deficient a-dystro-
glycanopathy is caused by a lack of cellular CDP-Rbo. To
examine whether supplementation of CDP-Rbo restores the
functional glycosylation of a-DG, we treated ISPD-deficient
HAP1 or HEK293 cells with exogenous CDP-Rbo (Figure 7F).
The addition of CDP-Rbo to the cell culture medium restored
the functional glycosylation of a-DG. In HEK293 cells, pretreat-
ment of CDP-Rbo with a transfection reagent increased the effi-
cacy of the restoration of a-DG glycosylation. These results raise
the possibility of CDP-Rbo supplementation as a treatment for
a-dystroglycanopathy patients.CeDISCUSSION
Our data demonstrate that tandem Rbo5P is a ‘‘post-phos-
phoryl moiety.’’ The structure required for the functional
maturation of a-DG was determined to be ‘‘Rbo5P-1Rbo5P-
3GalNAcb1,3GlcNAcb1,4Man(6P)-O’’ (Figure 6D). Post-phos-
phoryl modifications, including LARGE-dependent Xyl/GlcA re-
peats, have been thought to extend from phosphorylated Man
(Yoshida-Moriguchi et al., 2010); however, our present data
indicate that the monoester-linked phosphate on the C6-posi-
tion of O-Man exists independently of the HF-sensitive Rbo5P
tandem structure and that the Xyl/GlcA repeats extend from
the tandem Rbo5P. We speculate that mannosyl phosphor-
ylation determines the substrate specificity of Rbo5P and/or
Xyl/GlcA modifications. Recently, B4GAT1 was shown to be a
GlcA transferase, which synthesizes an acceptor primer neces-
sary for LARGE-dependent Xyl/GlcA repeat formation (Praiss-
man et al., 2014; Willer et al., 2014). Structure736 contains a
LARGE-independent Xyl/GlcA unit, which can be elongated
by LARGE activity (Figures 2 and S1). These data also confirm
that the Rbo5P tandem structure is a central part of the post-
phosphoryl moiety and is required for the functions of a-DG.
We subsequently identified the activities of three a-dystrogly-
canopathy-causing proteins, namely, ISPD, fukutin, and FKRP,
to be involved in Rbo5P glycosylation (Figure 6D). ISPD is a
CDP-Rbo synthase that uses Rbo5P and CTP. This finding sug-
gests that cellular levels of Rbo5P and CTP may control the
Rbo5P modification of a-DG. In bacteria, Rbo5P is synthesized
by the TarJ enzyme from ribulose 5-phosphate and nicotinamide
adenine dinucleotide phosphate (Brown et al., 2013). In mam-
mals, however, neither the ortholog of TarJ nor the biosynthetic
pathway of Rbo5P is currently known. It is hence important in the
future to identify proteins that are involved in mammalian Rbo5P
biosynthesis, because theymay regulate the functional glycosyl-
ation of a-DG and thus may cause a-dystroglycanopathy upon
their mutations.
Fukutin and FKRP are both Rbo5P transferases that use CDP-
Rbo as a common donor substrate. On the other hand, the selec-
tivity of fukutin and FKRP for acceptor substrates showed a
distinct difference: FKRP and fukutin are not able to transfer
Rbo5P to GalNAc and to the first Rbo5P residue, respectively.
Thus, formation of the tandem Rbo5P structure likely needs to
be performed in a sequential manner. In addition, we have not
observed polymer formation of more than two Rbo5P residues
by the activities of fukutin or FKRP. These data suggest the ex-
istence of strict mechanisms that determine substrate specificity
or regulate the formation of the tandem RboP structure. It is un-
knownwhether negative regulatory factors of the tandem Rbo5P
structure exist, for example, phosphodiesterase-like activities
that cleave the internal phosphodiester linkage of the Rbo5P tan-
dem structure. If such activities exist, they may be able to regu-
late the functional glycosylation of a-DG, and the elevated
expression or hyperactivation of such enzymes may result in
the abnormal glycosylation of a-DG.
Several studies have suggested the Golgi localization of
fukutin and FKRP based on the localization of exogenously
expressed proteins (Kobayashi et al., 1998; Esapa et al.,
2002). Our fractionation and enzyme assays also suggest thatll Reports 14, 2209–2223, March 8, 2016 ª2016 The Authors 2215
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Figure 5. Fukutin and FKRP Are Rbo5P Transferases
(A and B) Enzyme reaction of fukutin. PhosphoCoreM3-peptide was used as an acceptor substrate for s-fukutin. S, unreacted acceptor substrate. P1, s-fukutin
enzyme product. PhosphoCoreM3-peptide and the fraction containing the s-fukutin products (S and P1 in A) were analyzed by MS in the negative ion mode (B).
(C) The activities of s-fukutin with disease-causing mutations (p.M133T and p.R307Q) and with a mutation in the putative catalytic sites (p.D317A).
(legend continued on next page)
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endogenous fukutin and FKRP activities are localized in the
Golgi. Given that the LARGE-dependent Xyl/GlcA repeat is
also synthesized in the Golgi (Yoshida-Moriguchi et al., 2013),
we propose that the Rbo5P modification occurs in the Golgi
apparatus. We showed that some disease-causing missense
mutations in fukutin or FKRP proteins directly reduced their
enzyme activity, but the mislocalization of these proteins con-
taining disease-causing missense mutations has been also re-
ported (Esapa et al., 2002; Tachikawa et al., 2012). A protein
motif search and deglycosylation experiments suggested that
both fukutin and FKRP are N-glycosylated proteins (data not
shown). Mutations in their potential glycosylation sites may
cause a-dystroglycanopathy by altering the cellular localization
of or the protein stability of fukutin and FKRP. Indeed, amissense
mutation in the potential glycosylation site of FKRP (p.S174C)
has been reported (Quijano-Roy et al., 2006).
Recent studies reported that ISPD mutations are a relatively
common cause of a-dystroglycanopathy (Willer et al., 2012;
Roscioli et al., 2012; Cirak et al., 2013). In Japan, most cases
of a-dystroglycanopathy are confirmed to be FCMD, which is
caused by mutations in fukutin (Kobayashi et al., 1998; Matsu-
moto et al., 2005). LGMD2I, which is caused by mutations in
FKRP, is a common form of LGMD in western countries (Brock-
ington et al., 2001b). Taken together, a substantial proportion of
a-dystroglycanopathy is caused by abnormalities in the Rbo5P
glycosylation pathway. Although 18 genes are currently known
to cause abnormal glycosylation of a-DG upon their mutation,
resulting in a-dystroglycanopathy (Yoshida-Moriguchi and
Campbell, 2015), the causative genes for a proportion of a-dys-
troglycanopathy cases still remain to be identified. Some of the
as-yet-unidentified causative genes of a-dystroglycanopathy
may function in the Rbo5P glycosylation pathway, including
CDP-Rbo biosynthesis. Clarifying the Rbo5P glycosylation
pathway may accelerate our understanding of the pathogenesis
of a-dystroglycanopathy.
We showed that the addition of CDP-Rbo restored the
functional glycosylation of a-DG in ISPD-deficient cells, which
indicates that metabolic components such as Rbo5P and
CDP-Rbo in the Rbo5P glycosylation pathway can be targets
of molecular supplementation therapy for a-dystroglycanop-
athy. Although the glycosylation pattern of a-DG varies among
different cells and tissues, the IIH6-sensitive functional glycan
is present in many cells and tissues (Kuga et al., 2012). a-DG
in HEK293 and HAP cells contains functional glycans, and
gene editing and rescue experiments validated their suitability
for their use as disease model cells; however, further studies
using animal models will be necessary for the development of
CDP-ribitol supplementation therapy. Several lines of evidence
have established that abnormal glycosylation of a-DG contrib-
utes to the invasive and proliferative phenotypes of cancer cells
(Singh et al., 2004; Bao et al., 2009; Miller et al., 2015). Recently,
an association between the downregulation of ISPD and mortal-(D and E) Enzyme reaction of FKRP. Either PhosphoCoreM3-peptide (upper pane
for sFKRP. P1, unreacted acceptor substrate (s-fukutin product). P2, sFKRP enzy
by MS in the negative ion mode (E).
(F) The activities of sFKRP with a disease-causing mutation (p.Y307N) and with
See also Figure S4.
Ceity in clear cell renal cell carcinoma was reported (Miller et al.,
2015). Thus, our findings suggest the involvement of the
Rbo5P glycosylation pathway in tumor formation, as well as
the possibility of molecular CDP-Rbo supplementation as a
therapy for cancers.
Because Rbo5P has only been found in bacteria (Brown et al.,
2013) and some plants such as Adonis vernalis (Negm and Mar-
low, 1985), it is surprising that mammalian cells use Rbo5P as
a functional component of post-translational modifications.
Rbo5P is a component of the teichoic acids in bacterial cell
walls, which play various roles in bacterial physiology such
as cell shape determination, cell division, and host defenses
(Brown et al., 2013). How vertebrates acquired the Rbo5P modi-
fication during evolution, including the possibility of its horizontal
transmission, would be interesting to investigate. As for its phys-
iological functions, Rbo5P glycosylation is expected to be
involved in many biological processes, such as embryonic and
postnatal tissue development, as demonstrated by studies us-
ing fukutin and FKRP transgenic animals (Kurahashi et al.,
2005; Ackroyd et al., 2009; Kanagawa et al., 2013). An intriguing
question arises as to whether Rbo5P-containing glycoconju-
gates other than a-DG also exist. Given that DG-deficient
mice recapitulate aspects of fukutin- or FKRP-deficient a-dys-
troglycanopathies (Moore et al., 2002; Cohn et al., 2002),
a-DG is thought to be a primary target of Rbo5P modification.
We cannot exclude the possibility of the existence of a Rbo5P
transferase other than fukutin and FKRP, as well as that of a
Rbo5P-containing glycoprotein or glycolipid other than a-DG.
Investigating these possibilities will lead to a deeper under-
standing of Rbo5P modifications.
The complexity of the glycosylation machinery and the
possible existence of unidentified sugar units may hinder our un-
derstanding of glycosylation-dependent biological processes
and the pathogenesis of human diseases. We propose that
Rbo5P glycosylation is an essential modification in mammals
and that defects in the Rbo5P glycosylation pathway underlie
the pathogenesis of muscular dystrophy and possibly of cancer
metastasis and virus infection. Together, our results expand our
knowledge on post-translational modification and establish an
additional disease mechanism.EXPERIMENTAL PROCEDURES
Glycopeptide Purification from the DGFc Proteins
DGFc proteins were secreted into the cell culture media and recovered
with Protein A-beads. The DGFc proteins were eluted with 0.1 M glycine-
HCl (pH 2.5) and then neutralized with a final concentration of 0.2 M Tris-HCl
(pH 8.0). PreScission protease treatment to cleave the Fc tag was performed
according to the manufacturer’s instructions (GE Healthcare Life Science).
The cleaved Fc tag and the protease were removed by Protein A-beads and
glutathione beads, respectively. The samples were desalted using a Zeba
spin column (Life Technologies) and then freeze-dried. The freeze-dried
samples were dissolved with 20 mM phosphate buffer (pH 7.0) and treatedl) or the s-fukutin product (P1, lower panels) was used as an acceptor substrate
me product. The fraction containing the sFKRP products (P2 in D) was analyzed
a mutation in the putative catalytic site (p.D362A).
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with a2-3,6,8,9-neuraminidase (Merck Millipore) at 37C for 6 hr and then with
O-glycosidase (New England Biolabs) at 37C for 12 hr to remove the terminal
sialic acids and O-GalNAc-type glycans. The samples were subjected to an
anion exchange column (HiTrap Q XL beads, GE Healthcare Life Sciences)
and were fractionated by stepwise elution with NH4Ac (0.1, 0.25, 0.5, and
0.75 M). The fraction of the 0.5 M NH4Ac elution contained the DG-GPs
with Xyl/GlcA repeats, whereas the fraction of the 0.25 M NH4Ac elution
contained DG-GPs without Xyl/GlcA repeats. The fractions were freeze-dried
and then analyzed by MS or further purified by HPLC. For HPLC purification,
the freeze-dried samples were dissolved with 0.1% trifluoroacetic acid
(TFA), loaded onto an Inertsil ODS column (2.0 3 150 mm, GL Sciences),
and eluted with a linear gradient elution of acetonitrile (10%–50%) in 0.1%
TFA. To obtain a short glycopeptide (QIHATPTPVK) from DGFcT320K, the
glycopeptide (QIHATPTPVKAIGPPTTAIQEPP) separated by anion exchange
chromatography was digested with LEP (Wako Pure Chemicals Industries) in
50 mM ammonium bicarbonate and purified by HPLC using a PBr column
(COSMOSIL, Nacalai Tesque) with a linear gradient elution of acetonitrile
(10%–50%) in 0.1% TFA.
Mass Spectrometry
MALDI-TOF or nanoelectrospray ionization (nanoESI) MS was used to eluci-
date the glycopeptide structures. MALDI linear TOF measurements were car-
ried out on a Voyager DE Pro MALDI-TOF mass spectrometer equipped with a
nitrogen pulsed laser (337 nm) (Applied Biosystems). Typically, 0.1–1 pmol of
the glycopeptide samples was dissolved in a 1 ml solution of 10 mg/ml of 2,5-
dihydroxybenzoic acid (DHB) in a 0.1% TFA and 30% acetonitrile solution on a
MALDI sample target and dried. The measurements were carried out in posi-
tive ion mode. For MS/MS analysis, nanoESI MS was carried out using an LTQ
XL ion trap mass spectrometer (Thermo Fisher Scientific). The samples were
dissolved in a 50%methanol solution and directly infused into the mass spec-
trometer using a PicoTip emitter (New Objective). The measurements were
carried out in the negative ion mode. Typical nanoESI source conditions
were 1.6 kV source voltage, 42.8 V capillary voltage, and 200C capillary
temperature.
A high-resolution MS of Structure736 was carried out on an LTQ-Orbitrap
Velos Pro (Thermo Fisher Scientific) equipped with a nanoESI ion source in
the negative ion mode. The spray voltage was set at 0.8 kV, with a distance
of 3–5 mm between the top of the needle and the inlet of the mass spectrom-
eter. The resolution of the equipment was set at 100,000, and the capillary
temperature was set at 200C. The samples were dissolved in a 20% meth-
anol solution and then directly infused into the mass spectrometer using a
nanoESI tip (Cellomics Tip, HUMANIX). The electron multiplier gain, Fourier
transform, storage transmission, and mass accuracy were calibrated using
polytyrosine (m/z 180.06662, m/z 506.19327, and m/z 995.38326), according
to the manufacturer’s instructions. The prediction of the elemental composi-
tions from the measured accurate masses was performed by Kazusa Molec-
ular Formula Searcher and the exact mass database of Kazusa DNA Research
Institute.
Enzyme Assays for TarI and ISPD
The cDNA encoding TarI of Bacillus subtilis subsp. spizizenii TU-B-10 was
chemically synthesized by GenScript, cloned into the pET-22b(+) vector
(Merck Millipore), which was modified to lack the pelB signal sequence, and
expressed in Rosetta2 E. coli cells (Merck Millipore). The cells were ultra-son-
icated in Tris-buffered saline (TBS), and the recombinant TarI was purified
using COSMOGEL His-Accept. The expression vectors for human ISPDFigure 6. Structure of the Tandem Rbo5P Moiety
(A and B) 2D 1H-13C HSQC and 1H-31P HMBC spectra for the s-fukutin (A) and s
GalNAcb1,3GlcNAcb-pNp, black signals) and s-fukutin reaction product (Glycan2
spectra of the sFKRP product (Glycan3: Rbo’5P-1Rbo5P-3GalNAcb1,3GlcNAcb
(C) 1D 31P-NMR analysis. The s-fukutin and sFKRP products from the accept
purified DGT190M-GP6138 were analyzed. The variations in the 31P chemical shift
the pH of each sample, which could influence the chemical shift (Mo et al., 2011
(D) Schematic representation of the enzymatic activities of ISPD, fukutin, and FK
See also Figure S5.
Ceand its mutants were transfected into HEK293T cells using Effectene. The cells
were ultra-sonicated in TBS, and the ISPD proteins were purified using
COSMOGELHis-Accept. The bound proteins were elutedwith 0.5M imidazole
in TBS, concentrated, and buffer-exchanged into 20 mM Tris-HCl (pH 7.4) and
50mMNaCl using an AmiconUltra centrifugal filter unit. The ISPD reaction was
performed as previously reported, with modifications (Baur et al., 2009).
Briefly, the reaction mixture contained 100 mM MOPS-NaOH (pH 7.4),
10 mM MgCl2, 1 mM CTP, and 2 mM Rbo5P in a total volume of 40 ml and
was incubated for 2 hr at 37C. CDP-Rbo synthase activity was monitored
using an HPLC-based assay. The product was run on a 4.6 3 150 mm
COSMOSIL PBr column (Nacalai Tesque) by isocratic elution with 3% meth-
anol/97% 50 mM acetic acid-triethylamine (pH 7.3) at 30C and detected by
absorbance at 254 nm using the Prominence HPLC system. The separated
peak product was collected and lyophilized for MS.
Enzyme Assay for Fukutin and FKRP
The s-fukutin or sFKRP expression vectors were transfected into HEK293T
cells. The recombinant proteins were immunoprecipitated from the culture
supernatants with an agarose-conjugated anti-c-Myc antibody. The proteins
bound to agarose were used as the enzyme sources. The enzymatic reactions
were performed in a 50 ml reaction volume containing 100 mM MES (pH 6.5),
0.5 mM CDP-Rbo, 0.1 mM acceptor peptide, 10 mM MnCl2, 10 mM MgCl2,
0.5% Triton X-100, and 25 ml of the enzyme-bound agarose at 37C for
16 hr. PhosphoCoreM3-peptide and Rbo5P-phosphoCoreM3-peptide were
used as acceptors for s-fukutin and sFKRP, respectively. Each product
was separated by reversed-phase HPLC with a Mightysil RP-18GP Aqua
column (5 3 250 mm) (Kanto Chemical). Solvent A was 0.1% TFA in distilled
water, and solvent B was 0.1% TFA in acetonitrile. The peptide was eluted
at a flow rate of 1 ml/min using a linear gradient of 0%–40% solvent B. The
peptide separation wasmonitored by absorbance at 214 nm, and the products
P1 and P2 were analyzed by MS.
For the reaction using pNp-oligosaccharides as the acceptor substrates,
secreted s-fukutin and sFKRP were purified using COSMOGEL His-Accept
or cOmplete His-Tag Purification Resin (Roche). The bound protein was
eluted with 0.5 M imidazole in TBS, concentrated, and buffer-exchanged
into 20 mM Tris-HCl (pH 7.4) and 50 mM NaCl using an Amicon Ultra centrif-
ugal filter unit. The s-fukutin enzymatic reaction was performed in 2 mM
GalNAcb1,3GlcNAcb-pNp (Tokyo Chemical Industry), 4 mM CDP-Rbo,
10 mM MnCl2, 10 mM MgCl2, and 100 mM MOPS-NaOH (pH 7.4) for 16 hr
at 37C. The product was run on a 4.6 3 150 mm COSMOSIL 5C18-AR-II col-
umn (Nacalai Tesque) by isocratic elution with 12.5% acetonitrile/87.5%
50 mM ammonium acetate (pH 4.0) at 30C and detected by measuring the
absorbance at 300 nm using an HPLC system. The product was collected
and lyophilized for MS and NMR analyses. The FKRP enzymatic reaction
was performed in 1 mM Rbo5P-3GalNAcb1,3GlcNAcb-pNp (s-fukutin prod-
uct), 2 mM CDP-Rbo, 10 mM MnCl2, 10 mM MgCl2, and 100 mM MOPS-
NaOH (pH 7.4) for 16 hr at 37C. The product was run on a 4.6 3 150 mm
COSMOSIL 5C18-AR-II column by linear gradient elution with 0%–30% aceto-
nitrile/100%–70% 20 mM triethylamine acetate (pH 7.0) for 30 min at 30C
and detected by measuring the absorbance at 300 nm using HPLC system.
The separated peak sample was collected and lyophilized for MS and NMR
analyses.
NMR Analysis
The NMR spectra of pNP-derivatives and glycopeptides were recorded with
500 and 600 MHz spectrometers (BrukerBioSpin) using a 5-mm TXI cryogenicFKRP (B) products. NMR signals of the s-fukutin acceptor substrate (Glycan1:
: Rbo5P-3GalNAcb1,3GlcNAcb-pNp, red signals) are shown in layers (A). NMR
-pNp) are shown (B).
or substrates (GalNAcb1,3GlcNAcb-pNp and phosphoCoreM3-peptide) and
of the Man6P group between samples are most likely due to the differences in
).
RP, and the structure of the tandem Rbo5P moiety.
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probe, a BBO probe, and a Prodigy probe. The probe temperature was set
at 25C. The samples were dissolved in D2O (99.99 atom% D), and the
1H
chemical shifts were reported relative to the external standard of 4,4-
dimethyl-4-silapentane-1-sulfonic acid. The 13C and 31P chemical shifts
were calibrated using an indirect reference based on the X/1H resonance ratio
of 0.251449530 (13C/1H) and 0.404808636 (31P/1H). NMR signals were
assigned by a series of one- and two-dimensional measurements including
1D 1H, 1D 31P, 2D 1H-1H double quantum filtered-correlation spectroscopy
(DQF-COSY), homonuclear Hartmann-Hahn spectroscopy (HOHAHA), nu-
clear Overhauser effect spectroscopy (NOESY), 1H-13C HSQC, 1H-13C
HSQC-total correlation spectroscopy (TOCSY), and 1H-31P HMBC spectra.
The NMR data were processed with XWIN-NMR (ver. 3.5) and TopSpin
(ver 2.1), and the spectra were displayed using XWIN-PLOT (ver. 3.5).
Animal Study
All animal procedures were approved by the Animal Care and Use Committee
of Kobe University Graduate School of Medicine in accordance with the guide-
lines of the Ministry of Education, Culture, Sports, Science and Technology
(MEXT) and the Japan Society for the Promotion of Science (JSPS).
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(F) Rescue of the functional glycosylation of a-DG in ISPD-deficient cells by CDP-
exogenous CDP-Rbo. The a-DG preparations were analyzed by western blotting
control; lane 2, ISPD-deficient; lane 3, ISPD-deficient cells with CDP-Rbo; lane
deficient cells with Lipofectamine 2000.
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